What’s next for FDA

The rapid dismantling of Marty Makary’s FDA and replacement of ideological appointees with career officials signals a return to institutional norms that will be welcome to life sciences companies and patients after a year of turbulence. The journey won’t be smooth or swift, and the destination is far from certain.

Chris Klomp, a top HHS advisor, moved quickly after Makary’s departure, removing officials most closely associated with the former commissioner overnight. Administrative competence and agency experience now appear to matter more than fealty to President Donald Trump or fidelity to the MAHA movement...